It would be interesting to analyze whether NRF2 inhibition is also beneficial for those cancer types in which TIGAR abrogation has been shown to increase sensibility to radio- and chemotherapy, the case, for example, of glioblastoma [8,38]. Here, NFE2L2 is linked to glioblastoma.